涉及管理初始和复发性困难菌感染的治疗方法:最新的文献综述
Vignesh K Nagesh1, Hadrian Hoang-Vu Tran2, Daniel Elias2
1Department of Internal Medicine, Hackensack Palisades Medical Center, North Bergen, NJ 07047, United States. vgneshkrishnan@gmail.com.
World journal of gastrointestinal pharmacology and therapeutics
|September 16, 2024
概括
由于抗生素的使用改变了肠道微生物群,困难杆菌感染 (CDI) 正在增加. 正在探索新的治疗方法,以对抗高风险患者中日益增长的耐药性和复发性感染.
科学领域:
- 传染性疾病 传染性疾病
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 困难杆菌感染 (CDI) 发病率正在增加,与抗生素使用和肠道微生物组破坏有关.
- 复发性CDI和抗生素耐药性是重大挑战,特别是在老年人,重症监护和免疫功能低下的人群中.
- CDI可能会导致严重的并发症,如败血症休克和性结肠炎.
研究的目的:
- 审查目前对CDI的治疗方式.
- 探索CDI的新兴治疗方法和预防策略.
- 讨论与CDI治疗和耐药性相关的挑战.
主要方法:
- 对当前和新兴的CDI治疗方法的文献综述.
- 分析导致CDI复发和药物耐药性的因素.
- 检查新的治疗方法和预防措施.
主要成果:
- 有限的抗生素选择和日益增长的耐药性使CDI管理复杂化.
- 像贝兹洛托克苏马布和便微生物群移植等较新的治疗方法显示出有前途.
- 无症状携带者和耐药性对医疗保健系统构成威胁.
结论:
- 有效管理CDI需要解决抗生素耐药性和复发问题.
- 新的治疗方法和预防策略对于对抗CDI至关重要.
- 需要继续进行研究,以克服CDI治疗和预防方面的挑战.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
145
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
145
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
98
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
98
Drugs for Treatment of Ulcerative Colitis in IBD
130
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
130
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
111
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
111


